Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Change in Receivables (2025)

Kura Oncology (KURA) has disclosed Change in Receivables for 1 consecutive years, with -$27.1 million as the latest value for Q4 2025.

  • Quarterly Change in Receivables changed N/A to -$27.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.7 million through Dec 2025, changed N/A year-over-year, with the annual reading at $6.7 million for FY2025, 227.38% up from the prior year.
  • Change in Receivables for Q4 2025 was -$27.1 million at Kura Oncology, down from $31.4 million in the prior quarter.
  • The five-year high for Change in Receivables was $46.7 million in Q1 2025, with the low at -$44.2 million in Q2 2025.